Vidac Pharma (ISIN: GB00BM9XQ619), a clinical-stage biopharmaceutical company specializing in the development of a novel class of cancer treatments, has been awarded a patent by the United States Patent and Trademark Office (USPTO). This patent provides comprehensive protection for the mechanism of action underlying the Company's oncology and onco-dermatology therapeutic candidates.
News & Events